XTX Topco Ltd Acquires Shares of 14,395 NovoCure Limited (NASDAQ:NVCR)

XTX Topco Ltd purchased a new position in shares of NovoCure Limited (NASDAQ:NVCR) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,395 shares of the medical equipment provider’s stock, valued at approximately $429,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC increased its holdings in NovoCure by 1.3% in the third quarter. Geode Capital Management LLC now owns 2,405,257 shares of the medical equipment provider’s stock valued at $37,601,000 after buying an additional 29,871 shares during the last quarter. Tidal Investments LLC raised its stake in NovoCure by 4.6% during the third quarter. Tidal Investments LLC now owns 55,756 shares of the medical equipment provider’s stock worth $871,000 after acquiring an additional 2,465 shares during the period. Franklin Resources Inc. lifted its holdings in NovoCure by 222.6% in the third quarter. Franklin Resources Inc. now owns 180,853 shares of the medical equipment provider’s stock worth $2,904,000 after acquiring an additional 124,793 shares during the last quarter. Versant Capital Management Inc grew its holdings in shares of NovoCure by 35.8% during the fourth quarter. Versant Capital Management Inc now owns 3,341 shares of the medical equipment provider’s stock valued at $100,000 after purchasing an additional 880 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of NovoCure by 57.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider’s stock worth $129,000 after purchasing an additional 1,575 shares during the period. Institutional investors own 84.61% of the company’s stock.

NovoCure Price Performance

Shares of NovoCure stock opened at $15.58 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -11.13 and a beta of 0.65. The stock has a 50-day simple moving average of $18.83 and a 200-day simple moving average of $21.64. NovoCure Limited has a 52-week low of $11.70 and a 52-week high of $34.13.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.27). NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The company had revenue of $161.27 million for the quarter, compared to analyst estimates of $161.30 million. On average, equities research analysts expect that NovoCure Limited will post -1.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NVCR has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of NovoCure from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. StockNews.com raised NovoCure from a “sell” rating to a “hold” rating in a report on Thursday, April 17th. Wedbush dropped their price objective on NovoCure from $29.00 to $27.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of NovoCure in a report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, NovoCure has an average rating of “Moderate Buy” and a consensus price target of $34.17.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.